Shojiro Sawada
National Defense Medical College
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shojiro Sawada.
Biochemical Pharmacology | 1999
Hiroshi Yoshida; Toshitsugu Ishikawa; Hiroshi Hosoai; Michio Suzukawa; Makoto Ayaori; Tetsuya Hisada; Shojiro Sawada; Atsushi Yonemura; Kenji Higashi; Toshimitsu Ito; Kei Nakajima; Takeshi Yamashita; Koji Tomiyasu; Masato Nishiwaki; Fumitaka Ohsuzu; Haruo Nakamura
Dietary flavonoid intake has been reported to be inversely related to mortality from coronary heart disease, and the anti-atherosclerotic effect of flavonoids is considered to be due probably to their antioxidant properties. Oxidation of low density lipoprotein (LDL) has been reported to be induced by the constituent cells of the arterial wall. Accordingly, we examined the effect of pretreatment with tea flavonoids, such as theaflavin digallate, on the ability of cells to oxidize LDL. Theaflavin digallate pretreatment of macrophages or endothelial cells reduced cell-mediated LDL oxidation in a concentration- (0-400 microM) and time- (0-4 hr) dependent manner. This inhibitory effect of flavonoids on cell-mediated LDL oxidation was in the order of theaflavin digallate > theaflavin > or = epigallocatechin gallate > epigallocatechin > gallic acid. Further, we investigated the mechanisms by which flavonoids inhibited cell-mediated LDL oxidation using macrophages and theaflavin digallate. Theaflavin digallate pretreatment decreased superoxide production of macrophages and chelated iron ions significantly. These results suggest that tea flavonoids attenuate the ability of the cell to oxidize LDL, probably by reducing superoxide production in cells and chelating iron ions.
Arteriosclerosis, Thrombosis, and Vascular Biology | 2006
Makoto Ayaori; Shojiro Sawada; Atsushi Yonemura; Noriyuki Iwamoto; Masatsune Ogura; Nobukiyo Tanaka; Kazuhiro Nakaya; Masatoshi Kusuhara; Haruo Nakamura; Fumitaka Ohsuzu
Objective—The ATP-binding cassette transporter-A1 (ABCA1) regulates cholesterol efflux from cells and is involved in high-density lipoprotein metabolism and atherogenesis. The objective of this study was to investigate the effect of dexamethasone (Dex) and other glucocorticoid receptor (GR) ligands on apolipoprotein AI–mediated cholesterol efflux from macrophages and ABCA1 expression in them. Methods and Results—Dex, a GR agonist, decreased ABCA1 mRNA levels in a dose- and time-dependent fashion, and RU486, a GR antagonist, reversed the inhibitory effect of Dex. The effects of Dex and RU486 on ABCA1 protein levels and apolipoprotein AI–mediated cholesterol efflux from the macrophages were consistent with these changes in mRNA levels. Transfected RAW264.7, together with a human ABCA1 promoter–luciferase construct, inhibited transcriptional activity by Dex and overexpression of human GR. Transrepression by GR was not mediated by liver X receptor (LXR), because there were no differences in the effects of the GR ligands on promoter activity between a reporter construct with mutations at the LXR binding site and one without the mutations, and no changes were brought about in ABCG1 and ABCG4 expression by GR ligands. Conclusions—Our results showed that GR ligands affected ABCA1 expression and cholesterol efflux from macrophages, which are regulated by GR through a LXR-independent mechanism.
Acta Oncologica | 2005
Shojiro Sawada; Kazuhiko Sato; Masatoshi Kusuhara; Makoto Ayaori; Atsushi Yonemura; Kuniyoshi Tamaki; Hoshio Hiraide; Hidetaka Mochizuki; Fumitaka Ohsuzu
Endocrine therapies that profoundly decrease estrogen levels potentially have a detrimental effect on the cardiovascular system. This study evaluated the effect on lipid metabolism of one such agent, the new generation aromatase inhibitor anastrozole, compared with tamoxifen, when used as adjuvant treatment in postmenopausal Japanese women with early breast cancer. All patients had completed primary surgery and were randomized to anastrozole 1 mg once daily (n=22) or tamoxifen 20 mg once daily (n=22). Anastrozole significantly reduced levels of triglycerides and remnant-like particle cholesterol, whereas tamoxifen significantly increased these. Activity of lipoprotein lipase and levels of high-density lipoprotein cholesterol significantly increased after anastrozole treatment. In contrast, activity of hepatic triglyceride lipase, also a key enzyme of triglyceride metabolism, significantly decreased following treatment with tamoxifen. We thus conclude that in our study anastrozole had a beneficial effect on lipid profiles of postmenopausal women with early breast cancer after 12 weeks of treatment.
Arteriosclerosis, Thrombosis, and Vascular Biology | 2006
Nobukiyo Tanaka; Yukihiko Momiyama; Reiko Ohmori; Atsushi Yonemura; Makoto Ayaori; Masatsune Ogura; Shojiro Sawada; Masatoshi Kusuhara; Haruo Nakamura; Fumitaka Ohsuzu
To the EditornnHigh levels of osteopontin (OPN) mRNA and proteins were reported in atherosclerotic plaques.1,2 OPN-transgenic mice developed marked atherosclerosis.3 We reported plasma OPN levels to be high in patients with coronary artery disease (CAD) and to correlate with the severity of CAD.4 We also reported high plasma levels of OPN in patients with restenosis.5 These suggest that OPN plays a role in the development of atherosclerosis. In vitro, Takemoto et al6 demonstrated statins to reduce OPN mRNA in cultured aortic smooth muscle cells and upregulated OPN mRNA in aorta of diabetic rats.nnWe investigated the effects of 20 mg/d versus 5 mg/d atorvastatin on plasma OPN levels in 40 hypercholesterolemic patients without any history of cardiovascular disease. Our study was approved by institutional ethics committee. If patients were taking statins, these were discontinued. After 4-week washout period, fasting blood samples were taken after informed consent was obtained. If LDL-cholesterol >150 mg/dL, patients …
Journal of the American College of Cardiology | 2005
Atsushi Yonemura; Yukihiko Momiyama; Zahi A. Fayad; Makoto Ayaori; Reiko Ohmori; Kenji Higashi; Teruyoshi Kihara; Shojiro Sawada; Noriyuki Iwamoto; Masatsune Ogura; Hiroaki Taniguchi; Masatoshi Kusuhara; Masayoshi Nagata; Haruo Nakamura; Seiichi Tamai; Fumitaka Ohsuzu
Journal of Atherosclerosis and Thrombosis | 2007
Kazuhiro Nakaya; Makoto Ayaori; Tetsuya Hisada; Shojiro Sawada; Nobukiyo Tanaka; Noriyuki Iwamoto; Masatsune Ogura; Emi Yakushiji; Masatoshi Kusuhara; Haruo Nakamura; Fumitaka Ohsuzu
Atherosclerosis | 2008
Makoto Ayaori; Yukihiko Momiyama; Zahi A. Fayad; Atsushi Yonemura; Reiko Ohmori; Teruyoshi Kihara; Nobukiyo Tanaka; Kazuhiro Nakaya; Masatsune Ogura; Shojiro Sawada; Hiroaki Taniguchi; Masatoshi Kusuhara; Masayoshi Nagata; Haruo Nakamura; Fumitaka Ohsuzu
Nutrition Metabolism and Cardiovascular Diseases | 2008
Masao Takeshita; Yoshihisa Katsuragi; Masatoshi Kusuhara; Kenji Higashi; Emiko Miyajima; Kyoichi Mizuno; Kenta Mori; Tatsuo Obata; Reiko Ohmori; Fumitaka Ohsuzu; Yoshimitsu Onodera; Junko Sano; Shojiro Sawada; Shinji Tabata; Ichiro Tokimitsu; Kazuichi Tomonobu; Takeshi Yamashita; Takuji Yasukawa; Atsushi Yonemura; Haruo Nakamura
Nihon rinsho. Japanese journal of clinical medicine | 2006
Shojiro Sawada; Hidetsugu Saito; Masatoshi Kusuhara
Atherosclerosis | 2000
R. Hirano; Yukihiko Momiyama; K. Miyazaki; N. Isomura; N. Katayama; T. Hisada; Shojiro Sawada; Atsushi Yonemura; Kenji Higashi; T. Shibuya; Haruo Nakamura; Fumitaka Ohsuzu